Study of Quetiapine Treatment for Cannabis Dependence

Completed · Phase 2

Conditions studied: Cannabis Dependence

In brief

Marijuana is the most commonly used illicit drug in the United States. However, the treatment options for cannabis dependence are limited; notably, no effective pharmacotherapy has been developed. Conceptually, the ideal medication treatment for cannabis dependence would: 1. be safe when administered to patients actively using cannabis 2. reduce cannabis intake and promote abstinence 3. treat the symptoms of cannabis withdrawal 4. reduce craving and relapse risk 5. have a low abuse liability.

Key facts

Study ID

NCT00954681

Run by

New York State Psychiatric Institute

People needed

15

Starts

2009-08-01

Expected to finish

2010-08-01

Last updated by the study team

2019-04-24

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Between the ages of 18-65
• Meets DSM-IV criteria for current cannabis dependence
• Seeking treatment for cannabis dependence
• Reports using cannabis an average of five days per week over the past 28 days
• Capable of giving informed consent and complying with study procedures

You may not qualify if…

• Lifetime history of DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
• Current DSM-IV criteria for any other psychiatric disorder that may, according to the investigator's judgment, require either pharmacological or non-pharmacological intervention over the course of the study
• Receiving prescribed psychotropic medication
• Known history of allergy, intolerance, or hypersensitivity to quetiapine
• Pregnancy, lactation, or failure to use adequate contraceptive methods in female patients who are currently engaging in sexual activity with men
• Unstable medical conditions, such as poorly controlled diabetes or hypertension, which might make participation hazardous
• Current DSM-IV diagnosis of substance dependence other than cannabis or nicotine dependence
• Are legally mandated to participate in a substance use disorder treatment program
• Increased risk for suicide
• Diabetes (whether controlled or not), hyperglycemia (fasting glucose > 100 mg/dl), obesity (BMI > 30) and elevated lipids (cholesterol > 200 mg/dl; triglycerides > 150 mg/dl).

Where it is running

• Substance Treatment Research Service (STARS) of Columbia University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.